Skip to content

Author

Jonathan M. Meyer

We have 2 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder.

Objective: Once-monthly paliperidone palmitate (PP1M) extended-release injectable suspension is approved for the treatment of adults with schizophrenia or schizoaffective disorder. A 351 mg dose of PP1M (LY03010 [brand name Erzofri]) became available in the US in April 2025 and is approved as a single initiation inject...

Yong-Lin Chen, Lei-Jun Hu, Jonathan M. Meyer et al. · 0 citations
Review Jul 2026

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

Dopaminergic hyperactivity may be a key mechanism for core psychotic symptoms in many patients, but it is unlikely that dopamine dysregulation is a universal final common pathway across symptom domains.

M. Keshavan, Henry A. Nasrallah, A. Abi-Dargham et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.